| Literature DB >> 34484243 |
Dan Ma1, Bin Yang1, Baoyi Guan1, Luxia Song2, Qiyu Liu2, Yixuan Fan2, Lin Zhao2, Tongxin Wang2, Zihao Zhang2, Zhuye Gao1,3, Siming Li1,3, Hao Xu1,3.
Abstract
Background: Pyroptosis is a new programmed cell death discovered in recent years. Pyroptosis plays an important role in various diseases. Nevertheless, there are few bibliometric analysis systematically studies this field. We aimed to visualize the research hotspots and trends of pyroptosis using a bibliometric analysis to help understand the future development of basic and clinical research.Entities:
Keywords: CiteSpace; GSDMD; NLRP3; VOSviewer; caspase; programmed cell death; pyroptosis
Mesh:
Year: 2021 PMID: 34484243 PMCID: PMC8416445 DOI: 10.3389/fimmu.2021.731933
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Flowchart of literature selection.
Figure 2Trends of pyroptosis publications over the past 20 years.
Top 10 countries/regions and institutions related to pyroptosis.
| Rank | Country | Year | Centrality | Count (%) | Institution | Year | Centrality | Count (%) |
|---|---|---|---|---|---|---|---|---|
| 1 | China | 2010 | 0.00 | 1302 (45.76%) | Chinese Acad Sci (China) | 2010 | 0.20 | 67 (2.36%) |
| 2 | USA | 2005 | 0.05 | 905 (31.81%) | St Jude Children’s Res Hosp (USA) | 2011 | 0.01 | 65 (2.28%) |
| 3 | Germany | 2010 | 0.05 | 163 (5.73%) | Shanghai Jiao Tong Univ (China) | 2016 | 0.00 | 64 (2.25%) |
| 4 | Australia | 2009 | 0.01 | 125 (4.39%) | Harbin Med Univ (China) | 2014 | 0.01 | 62 (2.18%) |
| 5 | Japan | 2007 | 0.00 | 117 (4.11%) | Sun Yat Sen Univ (China) | 2018 | 0.01 | 56 (1.97%) |
| 6 | France | 2009 | 0.05 | 94 (3.30%) | Nanjing Med Univ (China) | 2016 | 0.08 | 52 (1.83%) |
| 7 | England | 2007 | 0.29 | 86 (3.02%) | Fudan Univ (China) | 2016 | 0.04 | 51 (1.79%) |
| 8 | Brazil | 2010 | 0.00 | 75 (2.64%) | Ghent Univ (Belgium) | 2008 | 0.04 | 48 (1.69%) |
| 9 | Canada | 2007 | 0.00 | 68 (2.39%) | Harvard Med Sch (USA) | 2016 | 0.00 | 48 (1.69%) |
| 10 | South Korea | 2012 | 0.00 | 63 (2.21%) | Southern Med Univ (China) | 2018 | 0.00 | 47 (1.65%) |
Figure 3Distribution of publications from different countries/regions.
Figure 4Distribution of publications from different institutions.
Top 10 authors and co-cited authors related to pyroptosis.
| Rank | Author | Count (%) | Centrality | Co-cited author | Citation | Centrality |
|---|---|---|---|---|---|---|
| 1 | Thirumaladevi Kanneganti | 50 (1.76%) | 0.04 | Shi JJ | 1127 | 0.01 |
| 2 | Mohamed Lamkanfi | 23 (0.81%) | 0.01 | Kayagaki N | 895 | 0.02 |
| 3 | Petr Broz | 22 (0.77%) | 0.13 | Miao Ea | 717 | 0.00 |
| 4 | Feng Shao | 22 (0.77%) | 0.18 | Lamkanfi M | 673 | 0.00 |
| 5 | Hao Wu | 22 (0.77%) | 0.09 | Bergsbaken T | 649 | 0.00 |
| 6 | Edward A Miao | 20 (0.70%) | 0.02 | Fink SL | 626 | 0.01 |
| 7 | Rajendra Karki | 19 (0.67%) | 0.02 | Broz P | 625 | 0.02 |
| 8 | Dario S Zamboni | 16 (0.56%) | 0.04 | Martinon F | 622 | 0.01 |
| 9 | Yan Wang | 15 (0.53%) | 0.02 | Liu X | 546 | 0.01 |
| 10 | Si Ming Man | 14 (0.49%) | 0.02 | Man SM | 539 | 0.00 |
Figure 5CiteSpace visualization map of authors involved in pyroptosis.
Top 10 journals and co-cited journals related to pyroptosis.
| Rank | Journal | Count (%) | IF (2020) | JCR | Co-cited journal | Citation | IF (2020) | JCR |
|---|---|---|---|---|---|---|---|---|
| 1 | Frontiers in immunology | 90 (3.16%) | 7.561 | Q2 | Nature | 11443 | 49.962 | Q1 |
| 2 | Cell death&disease | 73 (2.57%) | 8.469 | Q1 | Proceedings of the national academy of sciences of the United States of America | 6283 | 9.580 | Q1 |
| 3 | Journal of immunology | 59 (2.07%) | 5.422 | Q2 | Journal of immunology | 6274 | 5.422 | Q2 |
| 4 | Biochemical and biophysical research communications | 44 (1.55%) | 3.575 | Q2 | Cell | 5503 | 41.582 | Q1 |
| 5 | Proceedings of the national academy of sciences of the United States of America | 36 (1.27%) | 9.580 | Q1 | Journal of biological chemistry | 5503 | 5.157 | Q1 |
| 6 | Cell death and differentiation | 36 (1.27%) | 15.828 | Q1 | Nature immunology | 4456 | 25.606 | Q1 |
| 7 | Plos pathogens | 36 (1.27%) | 6.823 | Q1 | Immunity | 4236 | 31.745 | Q1 |
| 8 | International journal of molecular sciences | 36 (1.27%) | 5.923 | Q2 | Science | 4187 | 47.728 | Q1 |
| 9 | European journal of immunology | 36 (1.27%) | 5.532 | Q1 | Cell death and differentiation | 3168 | 15.828 | Q1 |
| 10 | Scientific reports | 36 (1.27%) | 4.379 | Q1 | Plos one | 2832 | 3.240 | Q1 |
IF, impact factor; JCR, Journal Citation Reports.
Figure 6The dual-map overlay of journals on pyroptosis.
Top 10 co-cited references related to pyroptosis.
| Rank | Reference | Citation | Year | Centrality | Ref. |
|---|---|---|---|---|---|
| 1 | Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death | 856 | 2015 | 0.01 | ( |
| 2 | Caspase-11 cleaves gasdermin D for non-canonical inflammasome signaling | 631 | 2015 | 0.01 | ( |
| 3 | Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores | 499 | 2016 | 0.00 | ( |
| 4 | Pore-forming activity and structural autoinhibition of the gasdermin family | 427 | 2016 | 0.01 | ( |
| 5 | Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion | 389 | 2015 | 0.00 | ( |
| 6 | Inflammatory caspases are innate immune receptors for intracellular LPS | 364 | 2014 | 0.01 | ( |
| 7 | Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death | 352 | 2017 | 0.00 | ( |
| 8 | Non-canonical inflammasome activation targets caspase-11 | 346 | 2011 | 0.02 | ( |
| 9 | Mechanisms and functions of inflammasomes | 298 | 2014 | 0.00 | ( |
| 10 | Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin | 293 | 2017 | 0.00 | ( |
Figure 7CiteSpace visualization map of top 50 references with the strongest citation bursts involved in pyroptosis.
Top 10 keywords related to pyroptosis.
| Rank | Keywords | Count | Centrality | Rank | Keywords | Count | Centrality |
|---|---|---|---|---|---|---|---|
| 1 | pyroptosis | 1459 | 0.02 | 11 | expression | 302 | 0.02 |
| 2 | NLRP3 inflammasome | 764 | 0.01 | 12 | NF-κB | 259 | 0.04 |
| 3 | apoptosis | 687 | 0.02 | 13 | autophagy | 230 | 0.03 |
| 4 | activation | 662 | 0.02 | 14 | oxidative stress | 217 | 0.03 |
| 5 | cell death | 608 | 0.01 | 15 | macrophage | 206 | 0.03 |
| 6 | inflammasome | 587 | 0.01 | 16 | protein | 191 | 0.03 |
| 7 | GSDMD | 455 | 0.01 | 17 | necroptosis | 188 | 0.01 |
| 8 | mechanism | 399 | 0.02 | 18 | death | 183 | 0.01 |
| 9 | caspase-1 | 395 | 0.02 | 19 | innate immunity | 180 | 0.01 |
| 10 | inflammation | 355 | 0.03 | 20 | receptor | 171 | 0.06 |
Figure 8CiteSpace visualization map of keywords clustering analysis related to pyroptosis.
Figure 9CiteSpace visualization map of timeline viewer related to pyroptosis.
The role of pyroptosis in different diseases.
| Disease | Promote (+)/Suppress (–) diseases | Model | Agent | Cell | Mechanism | Ref. |
|---|---|---|---|---|---|---|
| Epilepsy | – | rats | Chaihu-Longgu-Muli decoction | hippocampal neurons | reduce the expression of NLRP3, caspase-1 and IL-1β | ( |
| Atherosclerosis | – | apoE-/- mice | melatonin | endothelial cells | inhibit pyroptosis through MEG3/miR-223/NLRP3 axis; reduce the expression of GSDMD, IL-1β, IL-18, NF-κB | ( |
| Hepatocellular carcinoma | – | transgenic mice | sorafenib | macrophages | up-regulate caspase-1 | ( |
| Alcoholic liver disease | + | C57BL/6 mice | ethanol | hepatocytes | facilitate NLRP3 inflammasome activation | ( |
| Ischemic heart disease | – | H9c2 cells | liraglutide | H9c2 cells | inhibited the activation of NLRP3 inflammasome | ( |
| Atherosclerosis | – | cells | microRNA-30c-5p | human aortic endothelial cells | weaken the effect of caspase-1, IL-18, and IL-1β at protein level and transcriptional level | ( |
| Food-borne gastroenteritis | + | STAT1-/- mice | norovirus | macrophages | activate NLRP3 inflammasome | ( |
| Infectious and inflammatory diseases | – | wild-type mice | type I interferons | bone marrow | induced the expression of caspase-11 and GSDMD; activate NLRP3 inflammasome | ( |
| Colon cancer | – | cells | liver X receptor | colon cancer cells | activate NLRP3 inflammasome and caspase-1 through the P2RX7 pathway | ( |
| Diabetic nephropathy | + | rats | Long noncoding RNA MALAT1 | HK-2 human proximal tubular epithelial cells | activate NLRP3 inflammasome, caspase-1, IL-1β | ( |